US Edition
Breakthrough Cancer Test Predicts Whether Chemotherapy Will Work
- Cancer Research UK-funded scientists at Cambridge developed a DNA test on June 23, 2025, to predict chemotherapy resistance in tumors.
- They created the test to address the persistent issue that chemotherapy is often administered uniformly despite many cancers resisting treatment.
- Trial data from 840 patients showed the test can classify tumors as chemotherapy resistant or sensitive across platinum, anthracycline, and taxane treatments.
- Dr. Iain Foulkes emphasized that chemotherapy will no longer be administered as a uniform approach for all patients, signaling a shift toward more tailored and personalised cancer treatments.
- Researchers plan to seek regulatory approval for clinical use, which could reduce ineffective treatments and improve patient outcomes nationwide.
23 Articles
23 Articles
Cancer patients often do not respond to the therapy. An innovative test should now recognize this before – and thus advance cancer medicine.
Retentional prognosis: A newly developed test can predict whether a tumor reacts to three common chemotherapys or not. This could save cancer patients a lot of suffering and reduce their risk of ineffective and therefore unnecessary treatment.
The biologists Joe Sneath Thompson, Geoff Macintyre, Barbara Hernando, of the National Center for Oncological Research (CNIO), and Laura Madrid, of the company Tailor Bio, spin-off of the University of Cambridge (UK), presented this Monday together with other British and Spanish researchers a study in which they describe several markers able to predict whether cancer cells of a given person will respond to the large groups of chemotherapy: plati…
More subtle microsatellite instability better predicts fluorouracil insensitivity in colorectal cancer patients
Microsatellite instability (MSI) is now widely used as an indispensable biomarker. However, the relationship between MSI-H (high) and defective DNA mismatch repair (MMR) is not as straightforward as has been expected. Genome-edited cells carrying Lynch syndrome mutations do not exhibit drastic MSI typical in MSI-H (i.e. Type B) but more subtle MSI (i.e. Type A). In this study, we explored a connection between Type A MSI and 5-fluorouracil (5-FU)…
Coverage Details
Bias Distribution
- 60% of the sources are Center
To view factuality data please Upgrade to Premium
